[1]Fudan Univ, Sch Pharm, Dept Nat Prod Chem, 826 Zhangheng Rd, Shanghai 201203, Peoples R China;
[2]Fudan Univ, Sch Pharm, Dept Med Chem, 826 Zhangheng Rd, Shanghai 201203, Peoples R China;
[3]Shanghai Key Lab Clin Geriatr Med, 221 West Yanan Rd, Shanghai 200040, Peoples R China
Novel Ilomastat analogs with substituted benzamide groups, instead of hydroxamic acid groups, were designed, synthesized and evaluated against MMP-2 and MMP-9. Among these analogs, the most potent compound 10a exhibited potent inhibitory activity against MMP-2 with IC50 value of 0.19 nM, which is 5 times more potent than that of Ilomastat (IC50 = 0.94 nM). Importantly, 10a exhibited more than 8300 fold selectivity for MMP-2 versus MMP-9 (IC50 = 1.58 mu M). Molecular docking studies showed that 10a bond to the catalytic active pocket of MMP-2 by a non-zinc-chelating mechanism which was different from that of Ilomastat. Furthermore, the invasion assay showed that 10a was effective in reducing HEY cells invasion at 84.6% in 50 mu M concentration. For 10a, the pharmacokinetic properties had been improved and especially the more desirable t(1/2z) was achieved compared with these of the lead compound Ilomastat. (C) 2016 Elsevier Ltd. All rights reserved.